Trial Profile
Phase III, randomized, double-blind, active-controlled study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2016
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary) ; Pegfilgrastim
- Indications Breast cancer; Neutropenia
- Focus Registrational; Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 18 Nov 2014 The primary endpoint has been Met (Duration of severe neutropenia), according to the Teva Pharmaceutical media release.
- 01 Apr 2014 New trial record